It is therefore reasonable to hypothesize that targeting LINC02188 and ROCR in the Basal subtype and targeting LINC00511 in the Her2 and LumB subtype could reduce RNA methylation modification levels to inhibit tumor development. Here, ERBB2 is linked to neoplasm.